首页> 外文期刊>Journal of Clinical Oncology >Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer

【24h】

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer

机译：泛加拿大皮疹试验：一项随机III期试验，评估了预防性皮肤治疗方案对转移性肺癌患者表皮生长因子受体酪氨酸激酶抑制剂诱导的皮肤毒性的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第8期|共11页
作者
Melosky Barbara; Anderson Helen; Burkes Ronald L.; Chu Quincy; Hao Desiree; Ho Vincent; Ho Cheryl; Lam Wendy; Lee Christopher W.; Leighl Natasha B.; Murray Nevin; Sun Sophie; Winston Robert; Laskin Janessa J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer [J] . Melosky Barbara, Anderson Helen, Burkes Ronald L., Journal of Clinical Oncology . 2016,第8期

机译：泛加拿大皮疹试验：一项随机III期试验，评估了预防性皮肤治疗方案对转移性肺癌患者表皮生长因子受体酪氨酸激酶抑制剂诱导的皮肤毒性的影响
3. Association between Subjective Evaluation of Skin Toxicities and Quality of Life in Patients with Lung Cancer Undergoing Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Pilot Study for Developing Skin Toxicity Assessment [J] . Kengo Hirayama, Ya Su, Yasuyuki Ikezawa, Open Journal of Nursing . 2019,第12期

机译：肺癌经历表皮生长因子受体 - 酪氨酸激酶抑制剂治疗患者皮肤毒性和生活质量的主观评价与生活质量的关联 - 一种发展皮肤毒性评估的试验研究
4. A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer [J] . Ciruelos Eva, Apellániz‐Ruiz María, Cantos Blanca, The oncologist . 2019,第11期

机译：将Nab-PABlitaxel三剂量方案的神经毒性与基于溶剂的PACLITAXEL的神经毒性进行比较，作为人表皮生长因子受体2型2阴性转移患者的第一线治疗乳腺癌
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial) [O] . Oscar Arrieta, Amir Carmona, Maria Teresa de Jesus Vega, 2016

机译：皮肤传达了我们的深刻感受：抗生素预防性治疗可减少表皮生长因子受体抑制剂诱发的肺癌皮疹（泛加拿大皮疹试验）
7. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases [O] . Ling-Ling Kong, Lin-Lin Wang, Li-Gang Xing, 2017

机译：表皮生长因子受体 - 酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移患者临床试验的最新进展和结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号